| 1. |
加藤大悟、松原伸晃、石津谷 祐、山本致之、塩田真己、江藤正俊、安水洋太、田中伸之、大家基嗣、大澤崇宏、安部崇重、篠原信雄、西本紘嗣郎、小島崇宏、林 拓自、中山雅志、藤澤孝夫、中村能章、吉野孝之、野々村祝夫, Characteristics of metastaticrenal cell carcinoma via circulating tumor DNA: Nationwide SCRUM-Japan MONSTAR SCREEN study., 第21回日本臨床腫瘍学会学術集会, 2024.02. |
| 2. |
Takamatsu D, Eto M, Significance of CD73/adenosine receptor 2 (A2aR) and immune microenvironmental status in renal cell carcinoma with sarcomatoid changes and rhabdoid features., 2024 Genitourinary Cancers Symposium（ASCO-GU）, 2024.01. |
| 3. |
Matsubara N, Osawa T, Abe T, Oya M, Nishimoto K, Iwahori T, Tsuchiya H, Murota M, Yoshida M, Tatematsu Y, Nakano Y, Eto M, Nonomura N, Real world experience of FGFR gene alterations and clinical outcomes in advanced/metastatic urothelial cancer in Japan: MONSTAR-SCREEN database study., 2024 Genitourinary Cancers Symposium（ASCO-GU）, 2024.01. |
| 4. |
永川祥平、塩田真己、高松 大、塚原茂大、松元 崇、門司恵介、猪口淳一、小田義直、江藤正俊, Association of microsatellite instability with recurrence after bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer., 第75回西日本泌尿器科学会総会, 2023.11. |
| 5. |
家入康輔、垣内伸之、高松 大、牟田口 淳、小林 聡、後藤駿介、松元 崇、門司恵介、塩田真己、猪口淳一、井元清哉、小川誠司、江藤正俊, Genomic analysis of end-stage renal disease., 第75回西日本泌尿器科学会総会, 2023.11. |
| 6. |
Takamatsu D, Kohashi K, Oda Y, Eto M, Clinicopathological, immunohistochemical, and genetic study of TFE3 high expressive PRCC., The 39th JAPAN-KOREA Urological Congress, 2023.10. |
| 7. |
Ueda S, Ushijima M, Irie A, Senju S, Ito K, Hamana H, Kishi H, Ogasawara K, Udaka K, Eto M, Nishimura Y, Cancer vaccine improves the efficacy of Immune checkpoint blockade against refractory cancers., The 39th JAPAN-KOREA Urological Congress, 2023.10. |
| 8. |
Ueda S, Ushijima M, Irie A, Senju S, Ito K, Hamana H, Kishi H, Ogasawara K, Udaka K, Eto M, Nishimura Y, Cancer antigen vaccine enhances anti-tumor effects of immune checkpoint blockade against refractory cancers., AOS 2023 The 3rd International Congress of the Asian Oncology Society, 2023.10. |
| 9. |
Mutaguchi J, Morooka K, Goto S, Matsumoto T, Monji K, Shiota M, Inokuchi J, Eto M, The Efficacy of Red Channel Enhanced Images and Dilated Convolution for AI Segmentation of Bladder Tumors in Cystoscopic Images., AOS 2023 The 3rd International Congress of the Asian Oncology Society, 2023.10. |
| 10. |
Kobayashi S, Masaki F, King F，Wollin DA, Kibel AS, Hata N, Eto M, Feasibility of multi-section continuum robotic ureteroscope in the kidney., 43rd Congress of the Société Internationale d'Urologie (SIU), 2023.10. |
| 11. |
Tsukahara S, Shiota M, Uchiumi T, Matsumoto T, Nagakawa S, Kodama K, Goto S, Monji K, Inokuchi J, Eto M, cfDNA guiding with hotspot mutation in PLEKHS1 further improves early prediction of recurrence in muscle-invasive bladder cancer., 43rd Congress of the Société Internationale d'Urologie (SIU), 2023.10. |
| 12. |
Nagakawa S, Shiota M, Takamatsu D, Tsukahara S, Matsumoto T, Monji K, Inokuchi J, Oda Y, Eto M, Association of microsatellite instability with recurrence after bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer., 2023 The 2nd Annual Meeting of KUOS-EAUOS, 2023.09. |
| 13. |
Mutaguchi J, Oda Y, Goto S, Kobayashi S, Matsumoto T, Monji K, Shiota M, Inokuchi J, Mori K, Eto M, How much YOLO improves object detection accuracies compared to tiny-YOLO in cystoscopic images?, 2023 The 2nd Annual Meeting of KUOS-EAUOS, 2023.09. |
| 14. |
Eto M, Development of surgical navigation system and microsurgery robotics., TUA 2023 Annual Meeting, 2023.08. |
| 15. |
Ueda S, Ushijima M, Irie A, Nishimura Y, Eto M, Tumor associated antigen vaccine enhances anti-tumor effects of immune checkpoint inhibitors against refractory cancers., AUA 2023 Annual Meeting, 2023.04. |
| 16. |
Goto S, Tamada K, Eto M, Immunophenotype Analysis of Tumor-infiltrating Immune Cells to Elucidate the Mechanism of Antitumor Effect of IL-7 and CCL19 Producing CAR-T Cells against Solid Cancer., AUA 2023 Annual Meeting, 2023.04. |
| 17. |
Nonomura N, Kato T, Yamamoto Y, Ishizuya Y, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Kojima T, Hayashi T, Nakayama M, Fujisawa T, Nakamura Y, Bando H, Yoshino T, Matsubara N, Current Status and Future Perspective of Liquid Biopsy in Urological Cancers: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project., 第110回日本泌尿器科学会総会, 2023.04. |
| 18. |
Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Tokunaga S, Eto M, Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial., 第110回日本泌尿器科学会総会, 2023.04. |
| 19. |
Ieiri K, Kakiuchi N, Hirano T, Nishimura T, Watanabe K, Tanaka H, Miyano S, Takamatsu D, Monji K, Kashiwagi E, Shiota M, Inokuchi J, Eto M, Ogawa S, Genomic analysis of end-stage renal disease. , AACR Annual Meeting 2023, 2023.04. |
| 20. |
Ueda S, Ushijima M, Irie A, Senju S, Ito K, Hamana H, Kishi H, Ogasawara K, Udaka K, Nishimura Y, Eto M, Tumor antigen vaccine enhances anti-tumor effects of immune checkpoint inhibitors against refractory cancers., 38th Annual EAU congress 2023, 2023.03. |
| 21. |
Takamatsu D, Kiyozawa D, Kohashi K, Goto S, Kinoshita F, Matsumoto T, Lee K, Monji K, Kashiwagi E, Shiota M, Inokuchi J, Oda Y, Eto M, Prognostic impact of CD73/adenosine receptor 2 (A2aR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features., 38th Annual EAU congress 2023, 2023.03. |
| 22. |
Goto S, Tamada K, Eto M, Immunophenotype analysis of tumor-infiltrating immune cells to elucidate the mechanism of antitumor effect of IL-7 and CCL19 producing CAR-T cells against solid cancer., 38th Annual EAU congress 2023, 2023.03. |
| 23. |
Kajioka S, Kareman E, Okabe A, Lee K, Yamaza T, Eto M, The challenge for the radical therapy against interstitial cystitis transplanting deciduous dental pulp stem cells., 38th Annual EAU congress 2023, 2023.03. |
| 24. |
Mutaguchi J, Morooka K, Kinoshita F, Matsumoto T, Monji K, Kashiwagi E, Shiota M, Inokuchi J, Eto M, The efficacy of red channel enhanced images for AI segmentation of bladder tumors in Cystoscopic., 38th Annual EAU congress 2023, 2023.03. |
| 25. |
Kashiwagi E, Shiota M, Monji K, Lee K, Matsumoto T, Inokuchi J, Eto M, Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer., 38th Annual EAU congress 2023, 2023.03. |
| 26. |
Kashiwagi E, Harano T, Shimizu K, Takamoto A, Tomita K, Osawa T, Sakuhara Y, Hongo F, Hirota T, Ushijima Y, Asayama Y, Miki J, Kiyomi F, Egawa S, Nasu Y, Shinohara N, Ukimura O, Nakano S, Arai Y, Eto M, Evaluation of the safety and effectiveness of cryoablation in the treatment of renal angiomyolipoma related to tuberous sclerosis complex: The Cryo-TSC., 2023 Genitourinary Cancers Symposium（ASCO-GU）, 2023.02. |
| 27. |
Matsumoto T, Goto S, Kinoshita F, Lee K, Monji K, Kashiwagi E, Shiota M, Inokuchi J, Eto M, Perioperative outcomes of Robot-Assisted Radical Cystectomy at Kyushu University Hospital., Asian-Pacific Congress of Robotic Laparoscopic Surgery 2022 (ACRLS 2022), 2022.12. |
| 28. |
Blas L, Shiota M, Takamatsu D,Kinoshita F, Matsumoto T, Lee K, Monji M, Kashiwagi E, Inokuchi J, Eto M, Novel Nomogram Predicting Biochemical Recurrence-Free Survival After Radical Prostatectomy., Asian Pacific Prostate Society(APPS) 2022, 2022.12. |
| 29. |
Eto M, Recent advances in surgical navigation and microsurgery robotics., The 38th KOREA-JAPAN Urological Congress, 2022.11. |
| 30. |
Matsumoto T, Goto S, Kinoshita F, Lee K, Monji K, Kashiwagi E, Shiota M, Inokuchi J, Eto M, Perioperative Outcomes of Robot-assisted Radical Cystectomy at Kyushu University Hospital in Japan., 42th Congress of the Société Internationale d'Urologie (SIU), 2022.11. |
| 31. |
上田翔平、牛島美保、入江 厚、千住 覚、伊藤甲雄、浜名 洋、岸 裕之、小笠原康悦、宇高恵子、西村泰治、江藤正俊, Tumor antigen vaccine enhances anti-tumor effects of Immune checkpoint inhibitors against refractory cancers., 第74回西日本泌尿器科学会総会, 2022.11. |
| 32. |
高松 大、孝橋賢一、清澤大裕、木下史生、家入康輔、小田義直、江藤正俊, TFE3 immunopositive papillary renal cell carcinoma: A clinicopathological and immunohistochemical, and genetic study., 第74回西日本泌尿器科学会総会, 2022.11. |
| 33. |
Lee K, Shiota M, Takamatsu D, Ushijima M, Blas L, Okabe A, Kajioka S, Goto S, Kinoshita F, Matsumoto T, Monji K, Kashiwagi E, Inokuchi J, Oda Y, Eto M, Denervation caused by extended pelvic lymph node dissection worsens early urinary continence after robot-assisted radical prostatectomy., 19th Urological Association of Asia Congress, 2022.10. |
| 34. |
Goto S, Tamada K, Eto M, IL-7 and CCL19 producing CAR-T cells enhance antitumor efficacy against solid cancer by preventing antigen-loss tumor relapse., 37th Annual EAU congress 2022, 2022.07. |
| 35. |
Goto S, Tamada k, Eto M, Anti-mesothelin human CAR-T cells producing IL-7 and CCL19 enhance antitumor efficacy against solid cancer in orthotopic and PDX mouse models., AOS 2022 2nd International Congress of Asian Oncology Society, 2022.06. |
| 36. |
Mutaguchi J, Oda M,Kashiwagi E, Inokuchi J, Mori K, Eto M, Automatic Detection of Bladder Tumors in Narrow-Band Imaging Cystoscopic Images by tiny-YOLO., CARS 2022 Computer Assisted Radiology and Surgery 36th International Congress and Exhibition, 2022.06. |
| 37. |
Osawa K, Bandara DSV, Nakadate R, Nagao Y,Akahoshi T, Eto M, Arata J, Compliant Multi-DOF Endoluminal Forceps with 2.5 mm in diameter., CARS 2022 Computer Assisted Radiology and Surgery 36th International Congress and Exhibition, 2022.06. |
| 38. |
Inokuchi J, Murata M, Kawano T, Kang JH, Kinoshita F, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Shiota M, Eto M, Activated protein kinase C-alpha as a simple test for urothelial cancer screening., 2022 ASCO Annual Meeting, 2022.06. |
| 39. |
Lee K, Eto M, Sanders K, Koh SD, A novel bladder fibrosis pathway through PDGFR&[alpha]+ cells associated with estrogen deficiency and replacement., AUA 2022 Annual Meeting, 2022.05. |
| 40. |
Shiota M, Ushijima M, Matsumoto T, Kashiwagi E, Inokuchi J, Eto M, An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer., AUA 2022 Annual Meeting, 2022.05. |
| 41. |
Goto S, Tamada K, Eto M, IL-7 and CCL19 producing CAR-T cells prevent antigen-loss tumor relapse and enhance antitumor efficacy against solid cancer., AUA 2022 Annual Meeting, 2022.05. |
| 42. |
Kashiwagi E, Nishie A, Asayama Y, Ushijima Y, Arai Y, Hatano T, Shinohara N, Egawa S, Ukimura O, Nasu Y, Miki J, Takamoto A, Kiyomi F, Nakano S, Eto M, Trials in Progress：Evaluation of safety and effectiveness of cryoablation in the treatment of renal angiomyolipoma related to tuberous sclerosis complex: The Cryo-TSC study., 2022 Genitourinary Cancers Symposium（ASCO-GU）, 2022.02. |
| 43. |
Eto M, Takagi T, Kimura G, Fukasawa S, Tamada S, Miura Y, Oya M, Sassa N, Anai S, Nozawa M, Sakai H, Yusa W, Ikezawa H, First-line (1L) lenvatinib (L) + pembrolizumab (P) or everolimus (E) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): Phase 3 CLEAR Japanese subset., 第109回日本泌尿器科学会総会, 2021.12. |
| 44. |
大澤崇宏、小島崇宏、武内在雄、杉元幹史、江藤正俊、三浪圭太、中井康友、植田浩介、伊藤陽一、村井祥代、北村 寛、西山博之、篠原信雄, Oncologic outcome and prognostic factor analysis in a multi-center cohort treated with axitinib for metastatic renal cell carcinoma., 第109回日本泌尿器科学会総会, 2021.12. |
| 45. |
Grünwald V, Motzer R, Porta C, Eto M, Powles T, Hutson TE, Alekseev B, Rha SY, Kopyltsov E, Méndez-Vidal MJ, Hong SH, Kapoor A, Gordoa TA, Goh JC, Merchan JR, Perini RF, Xing D, Mody K, Smith AD, Choueiri TK, Phase 3 trial of lenvatinib plus pembrolizumab or everolimus versus sunitinib monotherapy as a first-line treatment for patients with advanced renal cell carcinoma（RCC）（CLEAR study）., 第109回日本泌尿器科学会総会, 2021.12. |
| 46. |
木村 博子、水野 桂、成田伸太郎、塩田真己、藤本直浩、住吉崇幸、寺田直樹、後藤崇之、小林 恭、 小倉啓司、賀本敏行、江藤正俊、羽渕友則、中川英刀、桃沢幸秀、小川 修、赤松秀輔, Frequency of cancer-predisposing genes in advance Japanese prostate cancer patients and their clinical implications., 第109回日本泌尿器科学会総会, 2021.12. |
| 47. |
Kashiwagi E, Shiota M, Monji K, Lee K, Matsumoto T, Takeuchi A, Inokuchi J, Eto M, Testosterone level in seminal vesicle fluid is a better indicator of sexual function than serum testosterone in patients with prostate cancer., 22nd World Meeting on Sexual Medicine (WMSM 2021) , 2021.11. |
| 48. |
Naganuma H, Nishinakamura R, Eto M, Draining Effect on Maturation of the Transplanted Embryonic Kidney., 41st Congress of the Société Internationale d’Urologie, 2021.11. |
| 49. |
牟田口 淳、小田昌宏、木下史生、長沼英和、李 賢、門司恵介、武内在雄、塩田真己、猪口淳一、森 健策、江藤正俊, Developing Artificial Intelligence System for Automatically Detecting Bladder Tumors in Cystoscopic Images with Objective and Reproducible., 第73回西日本泌尿器科学会総会, 2021.11. |
| 50. |
塚原茂大、塩田真己、内海 健、松元 崇、高松 大、孝橋賢一、林 哲太郎、永川祥平、門司恵介、柏木英志、康 東天、江藤正俊, Resistance to chemotherapy with gemcitabine associated with DPYD in muscle invasive bladder cancers（MIBC）., 第73回西日本泌尿器科学会総会, 2021.11. |
| 51. |
Lee K, Lee H, Park SO, Choi PC, Ryoo SB, Corrigan R, Perrino B, Eto M, Sanders KM, Koh SD, Relationship of detrusor overactivity with detrusor PDGFR alpha positive cell in spinal code injury., The 37th KOREA-JAPAN Urological Congress, 2021.10. |
| 52. |
Mutaguchi J, Kobayashi S, Cho B, Lee K, Monji K, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Eto M, Perioperative Outcome in Robot-Assisted Partial Nephrectomy with Surgical Navigation System for Highly Complex Tumors., 38th World Congress of Endourology and Uro-Technology (WCET), 2021.09. |
| 53. |
Lee K, Simpson J, Lee H, Lauren Peri, Perrino B, Eto M, Koh S, Sanders K, A novel bladder fibrosis pathway through PDGFRα+ cells associated with estrogen deficiency and replacement., The 15th Pan-Pacific Continence Society Meeting (PPCS 2021), 2021.09. |
| 54. |
Lee K, Shiota M, Takamatsu D, Ushijima M, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Eto M, Correlation between pelvic lymph node dissection and urinary incontinence after robot assisted radical prostatectomy., AUA 2021 Annual Meeting, 2021.09. |
| 55. |
Mutaguchi J, Oda M, Kinoshita F, Monji K, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Mori K, Eto M, Deep Learning System for Automatic Detection of Bladder Tumors in Narrow-Band Imaging (NBI) Cystoscopic Images., AUA 2021 Annual Meeting, 2021.09. |
| 56. |
Goto S, Tamada K, Eto M, Anti-mesothelin human CAR-T cells producing IL-7 and CCL19 enhance antitumor efficacy against solid cancer in orthotopic and PDX mouse models., AUA 2021 Annual Meeting, 2021.09. |
| 57. |
Mutaguchi J, Oda M, Kinoshita F, Monji K, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Mori K, Eto M, Deep Learning System for Automatic Detection of Bladder Tumors in Cystoscopic Images., 36th Annual EAU congress 2021, 2021.07. |
| 58. |
Goto S, Tamada K, Eto M, Anti-mesothelin human CAR-T cells producing IL-7 and CCL19 enhance antitumor efficacy against solid cancer in orthotopic and PDX mouse models., 36th Annual EAU congress 2021, 2021.07. |
| 59. |
Takamatsu D, Kohashi K, Kiyozawa D, Kinoshita F, Shiota M, Eto M, Oda Y, Clinicopathological and prognostic significance of TFE3 in papillary renal cell carcinoma., 36th Annual EAU congress 2021, 2021.07. |
| 60. |
Motzer RJ, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Wang J, Pan J, Asfaw AA, He CS, Mody K, Cella D, Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)., 2021 ASCO 57nd Annual Meeting, 2021.06. |
| 61. |
Matsumoto R, Yonese J, Kawahara T, Miyake H, Matsubara N, Uemura H, Eto M, Azuma H, Obara W, Terai A, Fukasawa S, Suekane S, Nishiyama H, Phase I/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma., 2021 ASCO 57nd Annual Meeting, 2021.06. |
| 62. |
Ohuchida K, Shindo K,Moriyama T, Tsutsumi C, Nagai S, Ohtsuka T, Shimizu S, Eto M, Nakamura M, New method for DT reconstruction using anti-peristaltic gastrojejunostomy with physiological passage., 第33回日本内視鏡外科学会総会, 2021.03. |
| 63. |
Mutaguchi J, Kobayashi S, Cho B, Inokuchi J, Tatsugami K, Eto M, Surgical Navigation is Predictor for Shorter Ischemic Time in Robot-Assisted Partial Nephrectomy., 第33回日本内視鏡外科学会総会, 2021.03. |
| 64. |
Nagao Y, Yoshizumi T, Tomiyama T, Iseda N, Morinaga A, Inokuchi S, Kosai Y, Yoshiya S, Takeishi K, Toshima T, Itoh S, Harada N, Ikegami T, Akahoshi T, Mori M, Eto M, Antral resection might prevent de novo gastroesophageal reflux disease in sleeve gastrectomy., 第33回日本内視鏡外科学会総会, 2021.03. |
| 65. |
Monji K, Abe T, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Eto M, Predictive factor of hemodynamic instability in laparoscopic adrenalectomy for pheochromocytoma., 第33回日本内視鏡外科学会総会, 2021.03. |
| 66. |
Monji K, Lee K, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Eto M, Pre-surgical therapy of immune-checkpoint inhibitors for type 2 papillary renal cell carcinoma: a case report., 第18回日本臨床腫瘍学会学術集会, 2021.02. |
| 67. |
Matsubara N, Kato T, Fujisawa T, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Horasawa S, Kuramoto N, Nakamura Y, Taniguchi H, Yoshino T, Nonomura N, Landscape of genomic alterations of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN., 2021 Genitourinary Cancers Symposium（ASCO-GU）, 2021.02. |
| 68. |
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Kopyltsov E, Méndez-Vidal MJ, Hong SH, Kapoor A, Alonso-Gordoa T, Goh JC, Merchan JR, Smith AD, Mody K,
Perini RF, Xing D, Choueiri TK, Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)., 2021 Genitourinary Cancers Symposium（ASCO-GU）, 2021.02. |
| 69. |
Kobayashi S, Mutaguchi J, Monji K, Abe T, Imada K, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M, The preservation of more normal renal parenchyma improves the operated renal function decreased by partial nephrectomy., 第108回日本泌尿器科学会総会, 2020.12. |
| 70. |
Eto M, Multimodality Therapy For Metastatic RCC: International Considerations Panel., International Kidney Cancer Symposiums (IKCS) 2020, 2020.11. |
| 71. |
Ueda S, Irie A, Senju S, Eto M,Nishimura Y, Effective combination immunotherapy for chemoresistant mouse bladder cancer using peptide vaccines and PD-1 blockade., 第48回日本免疫学会学術集会, 2019.12. |
| 72. |
上田翔平、入江 厚、千住 覚、江藤正俊、西村泰治, Effective combination immunotherapy for chemoresistant mouse bladder cancer using peptide vaccines and PD-1 blockade., 第71回西日本泌尿器科学会総会, 2019.11. |
| 73. |
小林 聡、Jeung D、Cho B、牟田口 淳、Jung K、武内在雄、塩田真己、猪口淳一、立神勝則、橋爪 誠、Hong J、江藤正俊, Development of next-generation surgical navigation system in Robot-assisted partial nephrectomy., 第71回西日本泌尿器科学会総会, 2019.11. |
| 74. |
Eto M, A novel navigation system in robot-assisted partial nephrectomy., 2019 KUA Annual Meeting, 2019.11. |
| 75. |
Imada K, Kashiwagi E, Monji K, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M, Can preoperative CT findings predict the pathological outcome of robot-assisted radical prostatectomy?, 39th Congress of the Société Internationale d’Urologie, 2019.10. |
| 76. |
Eto M, Urological Association of Asian Symposium session;
UAA: Cancer, 39th Congress of the Société Internationale d’Urologie, 2019.10. |
| 77. |
Monji K, Imada K, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M, Nivolumab treatment for patients with metastatic renal cell carcinoma: A retrospective analysis in Kyushu University Hospital., The 36th KOREA-JAPAN Urological Congress, 2019.09. |
| 78. |
Eto M, Precision Medicine in Pharmacotherapy for Prostate Cancer Using Genetic Polymorphism., The 36th KOREA-JAPAN Urological Congress, 2019.09. |
| 79. |
Eto M, The role of surgery in the treatment of metastatic kidney cancer., The East Asia Urological Oncology Society 2019, 2019.09. |
| 80. |
Masaoka H, Ito H, Matsuo K, Eto M, 5-year relative survival rates among men aged ≥80 years with prostate cancer in Japan: potential overtreatment for localized cancer., 17th Urological Association of Asia Congress, 2019.08. |
| 81. |
Monji K, Inokuchi J, Imada K, Kashiwagi E,Takeuchi A, Shiota M, Tatsugami K, Eto M, Impact of preoperative ureteroscopy on intravesical recurrence in patients after nephroureterectomy in Kyushu University Hospital., 17th Urological Association of Asia Congress, 2019.08. |
| 82. |
Kashiwagi E, Shiota M, Imada K, Monji K, Takeuchi A, Inokuchi J, Tatsugami K, Eto M. , Relationship between body composition and hormone sensitivity for androgen deprivation therapy in metastatic prostate cancer patients., 2019 ASCO 55nd Annual Meeting, 2019.06. |
| 83. |
Shiota M, Onozawa M, Hinotsu S, Eto M, Naito S, Akaza A; Japan Study Group of Prostate Cancer (J-CaP), Family history in primary hormone therapy for prostate cancer from a community-based multi-institutional Japan-wide database., 2019 ASCO 55nd Annual Meeting, 2019.06. |
| 84. |
Umezu D, Okada N, Sakoda Y, Adachi K, Eto M, Tamada K, Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment., 34st Annual EAU Congress 2019, 2019.03. |
| 85. |
Kashiwagi E, Imada K, Shiota M, Takeuchi A, Inokuchi J, Tatsugami K, Eto M, Thick perirenal fat predicts the growth pattern of renal cell carcinoma., 2019 Genitourinary Cancers Symposium（ASCO-GU）, 2019.02. |
| 86. |
Inokuchi J, Kuroiwa K, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Tanikawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yamaguchi A, Matsuyama H, Ichikawa T, Ito K, Mizusawa J, Eba J, Naito S, The Urologic Oncology Study Group of Japan Clinical Oncology Group (JCOG), The role of adjuvant chemotherapy for pT2-4 upper urinary tract urothelial cancer: Exploratory analysis of large multi-institutional study (JCOG1110A)., 2019 Genitourinary Cancers Symposium（ASCO-GU）, 2019.02. |
| 87. |
Eto M, Current status and future perspectives of molecular targeted therapy against kidney cancer., The 35th KOREA-JAPAN Urological Congress, 2018.12. |
| 88. |
Monji K, Inokuchi J, Imada K, Kashiwagi K, Takeuchi A, Shiota M, Tatsugami K, Eto M, Impact of preoperative ureteroscopy on intravesical recurrence in patients after nephroureterectomy in Kyushu University Hospital., The 35th KOREA-JAPAN Urological Congress, 2018.12. |
| 89. |
牧 知子、梶岡俊一、波止 亮、今田憲二郎、江藤正俊, Elucidation of the novel alternative relaxation mechanism of Mirabegron in detrusor smooth muscle not via β3 adrenoceptor., 第70回西日本泌尿器科学会総会, 2018.11. |
| 90. |
Namitome R, Imada K, Maki T, Kajioka S, Eto M, Lower Urinary Tract Dysfunction in Patients with Neuromyelitis Optica Spectrum Disorder., 38th Congress of the Société Internationale d’Urologie, 2018.10. |
| 91. |
Imada K, Kiyoshima K, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M, Analysis of Bacillus Calmette-Guérin (BCG) therapy for the patients with urothelial carcinoma of the prostatic urethra., 38th Congress of the Société Internationale d’Urologie, 2018.10. |
| 92. |
Masaoka H, Matsuo K, Eto M, Effect of Polymorphisms in Alcohol-Metabolizing Enzymes on Bladder Cancer Risk Associated with Drinking Alcohol., 38th Congress of the Société Internationale d’Urologie, 2018.10. |
| 93. |
Eto M, Current Status and Future Perspectives regarding Biomarkers for Renal Cell Carcinoma., 38th Congress of the Société Internationale d’Urologie, 2018.10. |
| 94. |
Kobayashi S, Cho B, Tatsugami K, Huaulmé A, Jannin P, Hasizume M, Eto M, Surgical Navigation in robot-assisted partial nephrectomy improve operative duration and surgical skills., 36th World Congress of Endourology (WCE2018), 2018.09. |
| 95. |
Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Eto M, Missense polymorphism in HSD3B1 in Japanese men treated with primary androgen-deprivation therapy for metastatic prostate cancer., 2018 ASCO 54nd Annual Meeting, 2018.06. |
| 96. |
Matsumoto T, Uchiumi T, Shiota M, Imada K, Dejima T, Kashiwagi E, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M, Targeting mitochondrial oxidative phosphorylation induces apoptosis via ER stress selectively to CD44v9 positive cells with cancer stem cell-like properties: importance of plasticity., The 113th Annual Meeting AUA 2018, 2018.05. |
| 97. |
Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M, The important role of glycine N-methyltransferase in the proliferation of renal and urothelial carcinoma., The 113th Annual Meeting AUA 2018, 2018.05. |
| 98. |
Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M, SEMA3C drives cancer growth and treatment resistance via cognate ligand-independent activation., The 113th Annual Meeting AUA 2018, 2018.05. |
| 99. |
Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Regional distribution of lymph node metastasis in upper urinary tract urothelial cancer, sub-analysisof large multi-institutional study (JCOG1110A)., 第106回日本泌尿器科学会総会, 2018.04. |
| 100. |
Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M, Independent validation of missense polymorphism in HSD3B1 in Japanese men treated with primary androgen-deprivation therapy for metastatic prostate cancer., 16th Urological Association of Asia Congress, 2018.04. |
| 101. |
Inokuchi J, Kuroiwa K, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Tanikawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, et al., Regional distribution of lymph node metastasis in upper urinary tract urothelial cancer, sub-analysis of large multi-institutional study (JCOG1110A)., 33st Annual EAU Congress 2018, 2018.03. |
| 102. |
Takeuchi A, Shiota M, Kamiryo Y, Tatsugami K, Eto M, Rationale and possibility of intravesical Bacillus Calmette-Guerin therapy with cytokine against bladder cancer., 33st Annual EAU Congress 2018, 2018.03. |
| 103. |
Takeuchi A, Shiota M, Gleave ME, Ong CJ, Eto M, Combinational therapeutics targeting Semaphorin 3C with anticancer drugs in prostate cancer., 33st Annual EAU Congress 2018, 2018.03. |
| 104. |
Dejima T, Takeuchi A, Leong J, Tam K, Tombe T, Erho N, Black PC, Eto M, Gleave ME, Ong CJ, LIM-SH3 domain protein 1 promotes tumorgenesis in prostate cancer., 33st Annual EAU Congress 2018, 2018.03. |
| 105. |
Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M, Independent validation of missense polymorphism in HSD3B1 in Japanese men treated with primary androgen-deprivation therapy for metastatic prostate cancer., 2018 Genitourinary Cancers Symposium（ASCO-GU）, 2019.06. |
| 106. |
Masatoshi Eto, [Renal Cancer]
Update in the Treatment of mRCC, How to Use Immune Checkpoint Blockade., Advancements in Urology 2017: An AUA/JUA Symposium, 2017.01. |
| 107. |
Masatoshi Eto, Molecular Medicine: Shaping the Future/ Kidney Cancer., 36th Congress of the Société Internationale d’Urologie, 2016.10. |
| 108. |
Masatoshi Eto, Urology in Asia Symposium
SessionⅡ:Kidney, Ureter, Bladder, Penile Cancer., 36th Congress of the Société Internationale d’Urologie, 2016.10. |
| 109. |
Masatoshi Eto, Current Status and Future Perspective of Medical Treatment for RCC., 35th Congress of the Société Internationale d'Urologie, 2015.10. |
| 110. |
Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Naito S, Renal cancer treatment with recipient Iymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation., 30th Annual EAU Congress 2015, 2015.03. |
